Ibiayi Dagogo-Jack1, Alexa B Schrock2, Marina Kem3, Nicholas Jessop4, Jessica Lee2, Siraj M Ali2, Jeffrey S Ross5, Jochen K Lennerz6, Alice T Shaw1, Mari Mino-Kenudson7. 1. Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 2. Foundation Medicine, Inc., Cambridge, Massachusetts. 3. Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. 5. Foundation Medicine, Inc., Cambridge, Massachusetts; Departments of Pathology, Urology, and Oncology, Upstate Medical University, Syracuse, New York. 6. Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. 7. Center for Integrated Diagnostics, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: mminokenudson@partners.org.
Abstract
INTRODUCTION: Ten percent of NSCLCs harbor mutations in SMARCA4, the gene encoding the SWItch/Sucrose Non-Fermentable ATPase BRG1. In preclinical models, BRG1 inactivation increases tumor aggressiveness but enhances sensitivity to drugs that target oxidative phosphorylation and inhibit SMARCA2, EZH2, CDK4, or CDK6. To facilitate translation of preclinical findings into clinical studies exploiting these therapeutic vulnerabilities, we assessed the clinical features of patients with tumors harboring BRG1-inactivating mutations. METHODS: Data sets from Massachusetts General Hospital and Foundation Medicine were reviewed to determine the prevalence of SMARCA4-mutant NSCLC and describe its clinicopathologic characteristics. BRG1 expression was evaluated by immunohistochemistry and correlated with SMARCA4 mutations. Treatment outcomes were retrospectively assessed. RESULTS: We detected SMARCA4 genomic alterations in 9% (n = 117 of 1422) and 11% (n = 3188 of 27,281) of NSCLCs in the institutional and Foundation Medicine data sets, respectively. In both cohorts, truncating mutations comprised over one-third of SMARCA4 alterations. Twenty-nine of 64 SMARCA4-mutant NSCLCs (45%) assessed for BRG1 expression reported loss of expression, most (90%) of which had truncating SMARCA4 mutations. Overall, 84% (n = 26 of 31) of evaluated NSCLCs with truncating SMARCA4 mutations lacked BRG1 expression. Deficient BRG1 expression was predominantly detected in adenocarcinomas with co-occurring mutations in KRAS, TP53, KEAP1, and STK11. Among patients with BRG1-deficient NSCLC who received first-line platinum doublet chemotherapy (n = 11) or chemotherapy plus immunotherapy (n = 5), median progression-free survival was 38 days and 35 days, respectively. CONCLUSIONS: BRG1 deficiency is enriched in NSCLCs with truncating SMARCA4 mutations. Clinical outcomes are poor in this molecular subgroup, highlighting the importance of developing novel strategies to target unique vulnerabilities associated with the BRG1-deficient state.
INTRODUCTION: Ten percent of NSCLCs harbor mutations in SMARCA4, the gene encoding the SWItch/Sucrose Non-Fermentable ATPase BRG1. In preclinical models, BRG1 inactivation increases tumor aggressiveness but enhances sensitivity to drugs that target oxidative phosphorylation and inhibit SMARCA2, EZH2, CDK4, or CDK6. To facilitate translation of preclinical findings into clinical studies exploiting these therapeutic vulnerabilities, we assessed the clinical features of patients with tumors harboring BRG1-inactivating mutations. METHODS: Data sets from Massachusetts General Hospital and Foundation Medicine were reviewed to determine the prevalence of SMARCA4-mutant NSCLC and describe its clinicopathologic characteristics. BRG1 expression was evaluated by immunohistochemistry and correlated with SMARCA4 mutations. Treatment outcomes were retrospectively assessed. RESULTS: We detected SMARCA4 genomic alterations in 9% (n = 117 of 1422) and 11% (n = 3188 of 27,281) of NSCLCs in the institutional and Foundation Medicine data sets, respectively. In both cohorts, truncating mutations comprised over one-third of SMARCA4 alterations. Twenty-nine of 64 SMARCA4-mutant NSCLCs (45%) assessed for BRG1 expression reported loss of expression, most (90%) of which had truncating SMARCA4 mutations. Overall, 84% (n = 26 of 31) of evaluated NSCLCs with truncating SMARCA4 mutations lacked BRG1 expression. Deficient BRG1 expression was predominantly detected in adenocarcinomas with co-occurring mutations in KRAS, TP53, KEAP1, and STK11. Among patients with BRG1-deficient NSCLC who received first-line platinum doublet chemotherapy (n = 11) or chemotherapy plus immunotherapy (n = 5), median progression-free survival was 38 days and 35 days, respectively. CONCLUSIONS:BRG1 deficiency is enriched in NSCLCs with truncating SMARCA4 mutations. Clinical outcomes are poor in this molecular subgroup, highlighting the importance of developing novel strategies to target unique vulnerabilities associated with the BRG1-deficient state.
Authors: Chai Bandlamudi; Jessica A Lavery; Joseph Montecalvo; Azadeh Namakydoust; Natasha Rekhtman; Gregory J Riely; Adam J Schoenfeld; Hira Rizvi; Jacklynn Egger; Carla P Concepcion; Sonal Paul; Maria E Arcila; Yahya Daneshbod; Jason Chang; Jennifer L Sauter; Amanda Beras; Marc Ladanyi; Tyler Jacks; Charles M Rudin; Barry S Taylor; Mark T A Donoghue; Glenn Heller; Matthew D Hellmann Journal: Clin Cancer Res Date: 2020-07-24 Impact factor: 12.531
Authors: Manav Gupta; Carla P Concepcion; Caroline G Fahey; Hasmik Keshishian; Arjun Bhutkar; Christine F Brainson; Francisco J Sanchez-Rivera; Patrizia Pessina; Jonathan Y Kim; Antoine Simoneau; Margherita Paschini; Mary C Beytagh; Caroline R Stanclift; Monica Schenone; D R Mani; Chendi Li; Audris Oh; Fei Li; Hai Hu; Angeliki Karatza; Roderick T Bronson; Alice T Shaw; Aaron N Hata; Kwok-Kin Wong; Lee Zou; Steven A Carr; Tyler Jacks; Carla F Kim Journal: Cancer Res Date: 2020-07-20 Impact factor: 12.701
Authors: Sai Ma; Lindsay M LaFave; Arjun Bhutkar; Carla P Concepcion; Manyuan Liu; Lydia P DeAngelo; Jonathan Y Kim; Isabella Del Priore; Adam J Schoenfeld; Manon Miller; Vinay K Kartha; Peter M K Westcott; Francisco J Sánchez-Rivera; Kevin Meli; Manav Gupta; Roderick T Bronson; Gregory J Riely; Natasha Rekhtman; Charles M Rudin; Carla F Kim; Aviv Regev; Jason D Buenrostro; Tyler Jacks Journal: Cancer Discov Date: 2021-09-24 Impact factor: 38.272